Abstract
Visualizing treatment patterns and survival in metastatic breast cancer
Journal of clinical oncology, Vol.37(27_suppl), pp.316-316
09/20/2019
DOI: 10.1200/JCO.2019.37.27_suppl.316
Abstract
Abstract only
316
Background: Optimal treatment sequencing (i.e., the order in which drugs are given) for metastatic breast cancer (MBC) is unknown. We aimed to develop an approach to visualize treatment patterns and survival in MBC. Methods: This retrospective study utilized ASCO’s CancerLinQ Discovery® database generated from electronic health records. Subjects included 3,312 women aged ≥18 years who were diagnosed with and received treatment for MBC after 1980. Hormone receptor (HR) status was determined by concordant diagnosis and treatment records. Human epidermal growth factor (HER2) status was determined by delivery of HER2-targeted therapy. Ordered and administered treatments were included. We created spatiotemporal plots of treatment patterns for HR+/HER2-, HER2+, and triple negative (TN) MBC. Individuals were represented on the Y-axis, and time on the X-axis with development of MBC aligned at time 0. Treatment classes were identified by colors: hormone therapies in shades of red, chemotherapies in shades of blue, HER2-targeted therapies in shades of green, and novel therapies in shades of orange. Concurrent treatments were represented by split bars. An overlaid Kaplan-Meier curve allowed for observations about the relationship between survival and treatment. Results: We developed a novel visualization approach to simultaneously display heterogeneous, longitudinal treatments and survival. Median survival after first documentation of MBC was 3.1 (IQR 1.4-7.2), 1.3 (IQR 0.6-2.8), and 2.6 (IQR 1.0-5.2) years for HR+/HER2-, TN, and HER2+ MBC, respectively. Patients with longer survival often had long duration of initial therapy, suggesting a more indolent or responsive disease. Substantial heterogeneity in treatment sequencing was observed for HR+HER2- and TN cohorts. In the HER2+ cohort, HER2-targeted therapy was commonly administered for the duration of treatment with more homogeneous sequencing. Conclusions: This novel visualization approach allows for observing the relationship between treatment patterns and survival, which is challenging to demonstrate with traditional quantitative methods. This approach can generate hypotheses regarding impact of treatment patterns on survival.
Details
- Title: Subtitle
- Visualizing treatment patterns and survival in metastatic breast cancer
- Creators
- Aidan Gilbert - University of Alabama at BirminghamCourtney Williams - University of Alabama at BirminghamPravinkumar Kandhare - University of Alabama at BirminghamArie Nakhmani - University of Alabama at BirminghamStephen C. Meersman - American Society of Clinical OncologyElizabeth Garrett-Mayer - American Society of Clinical Oncology, Alexandria, VAMelinda Kaltenbaugh - American Society of Clinical OncologyAndres Azuero - University of Alabama at BirminghamStacey A. Ingram - University of Alabama at BirminghamMark E. Burkard - University of Wisconsin Carbone Cancer CenterSmita Bhatia - University of Alabama at BirminghamKelly Kenzik - University of Alabama at BirminghamGabrielle Betty Rocque - University of Alabama at Birmingham
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.37(27_suppl), pp.316-316
- Publisher
- AMER SOC CLINICAL ONCOLOGY; ALEXANDRIA
- DOI
- 10.1200/JCO.2019.37.27_suppl.316
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Grant note
Breast Cancer Research Foundation of Alabama.
- Language
- English
- Date published
- 09/20/2019
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984700649002771
Metrics
1 Record Views